DA
KYMR icon

Duality Advisers’s Kymera Therapeutics KYMR Stock Holding History

Duality Advisers’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,600
Closed -$382K – 641
2023
Q2 		$382K Buy
+16,600
New +$476K 0.05% 419

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Duality Advisers's KYMR Position: Q3 2023 in Review

Duality Advisers sold out of Kymera Therapeutics (KYMR) in Q3 2023, closing a stake of 16,600 shares — an estimated $382K sold.

Duality Advisers first reported a position in KYMR in Q2 2023 and held it in 1 quarter. The position peaked at $382K in Q2 2023. 121 funds tracked by Wall St. Rank hold KYMR as of Q3 2023.

  • Duality Advisers reported no remaining Kymera Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Duality Advisers sold 16,600 Kymera Therapeutics shares in Q3 2023, an estimated $382K.
  • Duality Advisers first reported a position in Kymera Therapeutics in Q2 2023 and held it in 1 quarter.
  • Duality Advisers's Kymera Therapeutics position peaked at $382K in Q2 2023.
  • 121 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2023.

Based on Duality Advisers's 13F filing for Q3 2023, filed 2 Nov 2023.